Buy Seroflo Inhaler

Seroflo Inhaler

Seroflo Inhaler: Comprehensive Patient Guide

1. Introduction

Seroflo Inhaler is a fixed-dose combination inhaler that delivers two active ingredients-fluticasone propionate (a corticosteroid) and salmeterol (a long-acting β₂-agonist). It belongs to the Asthma & Breathing therapeutic category and is supplied as a metered-dose inhaler (MDI). In the United Kingdom it is a prescription-only medicine, regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).

The inhaler is marketed in two strength options: 25 µg fluticasone propionate / 125 µg salmeterol per actuation and 25 µg fluticasone propionate / 250 µg salmeterol per actuation. The device is designed for oral inhalation and delivers a precise dose with each puff when used correctly.

2. Mechanism of Action

How Seroflo Works in the Body

• Fluticasone propionate is an inhaled corticosteroid (ICS). Once deposited in the airways it binds to glucocorticoid receptors, reducing the production of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. This anti-inflammatory effect diminishes airway swelling, mucus hyper-secretion, and hyper-responsiveness.
• Salmeterol is a long-acting β₂-adrenergic receptor agonist (LABA). Activation of β₂ receptors on bronchial smooth muscle triggers cyclic AMP production, which relaxes the muscle and produces bronchodilation that lasts up to 12 hours.
• The combination provides dual control: fluticasone addresses the underlying inflammation, while salmeterol maintains airway patency between rescue inhaler doses. The onset of bronchodilation occurs within minutes, the anti-inflammatory effect builds over days, and the overall therapeutic duration matches the twice-daily dosing schedule.

3. Approved Medical Uses

Conditions Treated by Seroflo Inhaler

• Maintenance treatment of asthma in adults and adolescents (≥12 years) who require both anti-inflammatory and long-acting bronchodilator therapy.
• Prevention of exercise-induced bronchospasm when used regularly as part of a broader asthma management plan.
• The inhaler is not indicated for acute bronchospasm; a short-acting bronchodilator (e.g., salbutamol) should be used for immediate relief.

4. Off-Label and Investigational Applications

No robust, peer-reviewed evidence currently supports off-label uses of Seroflo that would meet the article’s inclusion criteria.

5. Patient Suitability and Contraindications

Who Should (Not) Use Seroflo Inhaler?

• Absolute contraindications
• Known hypersensitivity to fluticasone propionate, salmeterol, or any other component of the inhaler.
• Patients experiencing an acute severe asthma attack or status asthmaticus; a rapid-acting bronchodilator is required instead.
• Relative contraindications
• Pregnancy & lactation: Fluticasone is classified as Category B (no evidence of fetal risk in animal studies) while salmeterol is Category C. Use only if the potential benefit outweighs risk.
• Severe cardiovascular disease (e.g., uncontrolled arrhythmias, recent myocardial infarction) - β₂-agonists may provoke tachycardia or tremor.
• Severe liver impairment - systemic absorption of fluticasone is increased, warranting careful monitoring.
• Special populations
• Elderly patients may be more sensitive to β₂-agonist side effects such as palpitations.
• Patients with diabetes should monitor glucose, as systemic corticosteroids can raise blood sugar.

If any of these conditions apply, a healthcare professional should assess the risk-benefit balance before prescribing Seroflo.

6. Safety Profile: Side Effects and Interactions

Common Side Effects

• Oral thrush (candidiasis) - reported in >1 % of users; mitigated by rinsing the mouth after inhalation.
• Hoarseness or dysphonia - mild, often resolves with technique adjustment.
• Headache - occasional, generally transient.
• Transient tremor - linked to the β₂-agonist component; usually mild.

Serious Adverse Events

• Paradoxical bronchospasm - rare but may require immediate medical attention.
• Systemic corticosteroid effects (e.g., adrenal suppression, osteoporosis) - uncommon at prescribed inhaled doses but possible with long-term high-dose use.
• Cardiac arrhythmias or significant tachycardia - may occur in patients with pre-existing heart disease.

Drug Interactions

• CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) can increase systemic fluticasone exposure, raising the risk of adrenal suppression.
• β-blockers (non-selective) may diminish the bronchodilator effect of salmeterol and precipitate bronchospasm.
• Diuretics (e.g., furosemide) can potentiate hypokalaemia when combined with salmeterol.
• Other bronchodilators (e.g., theophylline) may increase the likelihood of tachyarrhythmias.

Patients should provide a complete medication list, including over-the-counter drugs and herbal supplements, to their prescriber.

Food and Lifestyle Interactions

• No known food interactions; the inhaler can be used with or without meals.
• Alcohol consumption does not affect Seroflo’s efficacy, but excessive intake may exacerbate corticosteroid-related hyperglycaemia.
• Driving or operating machinery: Salmeterol can cause mild tremor or palpitations in some individuals; patients should assess personal tolerance.

7. Dosing and Administration Guidelines

How to Take Seroflo Inhaler

• Standard adult dosing (both strength options):
• 1 inhalation twice daily (morning and evening), spaced approximately 12 hours apart.
• The inhaler delivers 25 µg fluticasone propionate plus either 125 µg or 250 µg salmeterol per puff, depending on the prescribed strength.
• Missed dose:
• If a scheduled dose is missed and the next dose is more than 6 hours away, take the missed dose as soon as remembered.
• Do not double-dose to compensate for a forgotten inhalation.
• Inhaler technique (MDI):
• Shake the inhaler vigorously for 5 seconds before use.
• Exhale fully, place the mouthpiece between the lips, and start a slow, steady inhalation.
• Press the canister once during the inhalation, then continue breathing in for a few seconds.
• Hold breath for 5-10 seconds, then exhale slowly.
• Rinse the mouth with water (do not swallow) and expectorate to reduce the risk of oral thrush.
• Special populations:
• Renal impairment: No dose adjustment needed, but monitor for systemic corticosteroid effects.
• Hepatic impairment: Use the lowest effective dose and consider regular assessment of adrenal function.
• Elderly: Start with the lower strength (25/125 µg) and titrate based on response and tolerability.

Overdose Management

• Symptoms may include severe headache, nausea, vomiting, tremor, palpitations, or signs of cortisol excess (e.g., facial swelling).
• Action: Seek emergency medical care. Activated charcoal is not appropriate for inhaled medications; supportive care and monitoring are the mainstays.

Discontinuation

• Abrupt cessation is generally safe, but patients experiencing worsening asthma control should discuss a step-down plan with their prescriber.

8. Monitoring and Follow-Up

• Asthma control assessment (symptom diary, peak flow measurements) at each follow-up visit.
• Adrenal function testing (morning cortisol) may be considered for patients on high-dose fluticasone for longer than 3 months.
• Bone density monitoring for long-term high-dose corticosteroid users, especially if additional risk factors exist.
• Review inhaler technique at every visit; incorrect use reduces drug delivery and clinical benefit.

9. Storage and Handling

• Store the inhaler room temperature (15 °C-30 °C), away from direct sunlight, heat, and moisture.
• Keep the canister upright to ensure proper dosing.
• Do not expose the inhaler to frost or extreme temperatures (e.g., car glove compartment in winter).
• Replace the inhaler when the dose-counter indicates that only 20 puffs remain, even if the device appears functional.
• Disposal: Follow local NHS guidelines for hazardous waste; many community pharmacies accept used inhalers for safe disposal.

10. Medication-Specific Glossary

Corticosteroid-Induced Adrenal Suppression

A reduction in the body’s natural cortisol production caused by prolonged exposure to exogenous steroids, potentially leading to fatigue, hypotension, or shock during stress.

β₂-Agonist

A class of medication that stimulates β₂-adrenergic receptors in airway smooth muscle, causing relaxation and bronchodilation.

Inhaler Dose-Counter

A mechanical indicator on the inhaler that tallies the number of actuations remaining, helping patients track when a refill is needed.

Paradoxical Bronchospasm

An unexpected worsening of airway obstruction after inhaler use, requiring immediate medical evaluation.

11. Medical Disclaimer

This article provides educational information about Seroflo Inhaler and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.

12. FAQ